About the TRITON Trials

There are currently two ongoing TRITON (Trial of Rucaparib In ProsTate IndicatiONs) studies of rucaparib in metastatic castration-resistant prostate cancer (mCRPC) that are open for enrollment to men with advanced prostate cancer.

TRITON2 is a single-arm open-label Phase 2 study of men with mCRPC and specific gene alterations including BRCA, ATM and other HRD gene alterations. As part of this study, genetic testing results will be provided. Eligible patients must have progressed on at least one, but no more than two prior next-generation hormonal (aka androgen-receptor targeted) therapies and one prior taxane-based chemotherapy for the treatment of mCRPC. The primary endpoint of the study is response rate.

You may be eligible to participate in this trial if you:

  • Are at least 18 years of age
  • Have a type of prostate cancer called adenocarcinoma or have poorly differentiated carcinoma of the prostate
  • Have serum testosterone levels below target levels
  • Have experienced progression of your prostate cancer after treatment with 1 or 2 androgen receptor-targeted therapies (e.g. abiraterone acetate, enzalutamide), and 1 prior taxane-based chemotherapy (docetaxel or cabazitaxel), for castration-resistant disease
  • Had no prior treatment with any PARP inhibitor, mitoxantrone, cyclophosphamide or any platinum-based chemotherapy
  • Have a BRCA1/2 or ATM genetic alteration, or other DNA repair deficiency (note that genetic testing will be provided as part of participating in this trial)

Please visit www.ClinicalTrials.gov for more information on this trial.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02952534.


TRITON3 is a randomized open-label Phase 3 study evaluating the effects of rucaparib compared to physician’s choice of therapy for patients with mCRPC with specific gene alterations including BRCA and ATM. Not all patients will receive rucaparib. As part of this study, genetic testing results will be provided. Eligible patients must have progressed on one prior androgen-receptor targeted therapy and must not have received prior chemotherapy for castration-resistant prostate cancer. The primary endpoint of the study is progression-free survival.

You may be eligible to participate in this trial if you:

  • Are at least 18 years of age
  • Have a common type of prostate cancer called adenocarcinoma or have poorly differentiated carcinoma of the prostate
  • Have serum testosterone levels below target levels
  • Are eligible for treatment with your physician’s choice of comparator treatment (abiraterone acetate, enzalutamide or docetaxel)
  • Have experienced disease progression after treatment with an androgen-receptor targeted treatment (e.g., abiraterone acetate, enzalutamide) for castration-resistant disease
  • Had no prior treatment with any PARP inhibitor or with chemotherapy (such as docetaxel, mitoxantrone, cyclophosphamide, platinum-based agents) for mCRPC
  • Have an alteration in a BRCA1/2 or ATM gene (note that genetic testing will be provided as part of participating in this trial)

Please visit www.ClinicalTrials.gov for more information on this trial.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02975934.

Choosing to participate in a clinical trial is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about any of the studies described above, you or your doctor may contact the study research staff using the contacts provided on this website. For more information about participating in clinical trials visit:

http://www.cancer.gov/clinicaltrials/

http://clinicaltrials.gov/

The American Society of Clinical Oncology also has a series of videos, Preparatory Education About Clinical Trials (PRE-ACT), addressing common questions about clinical trials.

For more information about genetic testing in cancer visit the National Cancer Institute website:

https://www.cancer.gov/about-cancer/causes-prevention/genetics/genetic-testing-fact-sheet